MeiraGTx Holdings PLC (OQ:MGTX)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 450 E 29th St Fl 15
NEW YORK NY 10016-8367
Tel: N/A
Website: https://meiragtx.com
IR: See website
<
Key People
Alexandria Forbes
President, Chief Executive Officer, Director
Richard Giroux
Chief Financial Officer, Chief Operating Officer
Robert J. Wollin
General Counsel, Secretary
Stuart Naylor
Chief Development Officer
Robert K. Zeldin
Chief Medical Officer
 
Business Overview
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren's Syndrome; AAV-GAD for the treatment of Parkinson's Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
Financial Overview
For the fiscal year ended 31 December 2023, MeiraGTx Holdings PLC revenues decreased 12% to $14M. Net loss decreased 35% to $84M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Foreign currency loss increase from $9.5M (expense) to $9.3M (income), Interest income increase from $777K to $2.3M (income).
Employees: 419 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $264.09M as of Dec 31, 2023
Annual revenue (TTM): $14.02M as of Dec 31, 2023
EBITDA (TTM): -$123.33M as of Dec 31, 2023
Net annual income (TTM): -$84.03M as of Dec 31, 2023
Free cash flow (TTM): -$125.54M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 64,306,613 as of Apr 9, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.